Related Experiment Video
Updated: Mar 28, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
Published on: January 17, 2025
Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections
William E Sause1, Peter T Buckley2, William R Strohl2
1Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA.
Abstract:
The growing incidence of serious infections mediated by methicillin-resistant Staphylococcus aureus (MRSA) strains poses a significant risk to public health. This risk is exacerbated by a prolonged void in the discovery and development of truly novel antibiotics and the absence of a vaccine. These gaps have created renewed interest in the use of biologics in the prevention and treatment of serious staphylococcal infections. In this review, we focus on efforts towards the discovery and development of antibody-based biologic agents and their potential as clinical agents in the management of serious S. aureus infections. Recent promising data for monoclonal antibodies (mAbs) targeting anthrax and Ebola highlight the potential of antibody-based biologics as therapeutic agents for serious infections.
Related Concept Videos
Staphylococcal Skin Infections
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Drug Products: Biologics, Biosimilars and Interchangeables
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...

